U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H35N5O5
Molecular Weight 581.6615
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERGOTAMINE

SMILES

CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O

InChI

InChIKey=XCGSFFUVFURLIX-VFGNJEKYSA-N
InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H35N5O5
Molecular Weight 581.6615
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

The isolation and naming of ergotamine by Stoll occurred in 1925 but the complete elucidation of structure was not achieved until 1951, with synthesis following some 10 years later. Current sources of ergotamine include the isolation from field ergot and fermentation broth, as well as synthesis via coupling of (+)-lysergic acid with the appropriate synthetic peptidic moiety. Ergotamine was introduced into world commerce in 1921, and is currently marketed as its water soluble tartrate salt. Ergotamine is a partial agonist at various tryptaminergic receptors (including the serotonin receptor [5-HT2]) and at various α-adrenergic receptors in blood vessels and various smooth muscles. It is likely that the major activity of ergotamine and related alkaloids is one of agonism at the 5-HT1B/1D receptors, just as with the “triptan” antimigraine compounds. FDA-labeled indications for ergotamine tartrate are in the abortion or prevention of vascular headaches, such as migraine, migraine variant, cluster headache, and histaminic cephalalgia.

Originator

Curator's Comment: In 1918 Arthur Stoll patented the isolation of ergotamine tartrate, which was subsequently marketed by Sandoz in 1921.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ERGOMAR

Approved Use

Ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or a so-called "histaminic cephalalgia".

Launch Date

1983
Primary
CAFERGOT

Approved Use

Treatment of acute attacks of migraine with or without aura in adults.
Primary
MIGERGOT

Approved Use

MIGERGOT is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia.” Ergotamine tartrate and caffeine suppositories should only be used for migraine headaches as they are not effective for other types of headaches and they lack analgesic properties.

Launch Date

1983
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
454 pg/mL
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
21.4 pg/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1216 pg × h/mL
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
61 pg × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.38 ng × h/mL
3.89 μg/kg bw single, intravenous
dose: 3.89 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.04 ng × h/mL
1.94 μg/kg bw single, intravenous
dose: 1.94 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.36 ng × h/mL
1.01 μg/kg bw single, intravenous
dose: 1.01 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.35 h
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.15 h
3.89 μg/kg bw single, intravenous
dose: 3.89 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.13 h
1.94 μg/kg bw single, intravenous
dose: 1.94 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.08 h
1.01 μg/kg bw single, intravenous
dose: 1.01 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting (severe)
Dizziness
Blood pressure decreased
Peripheral vasoconstriction
Paresthesia
Cyanosis peripheral
Angina
Sources:
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Disc. AE: Depression, Vertigo...
AEs leading to
discontinuation/dose reduction:
Depression
Vertigo
Blurred vision
Arrhythmia
Hypersensitivity
Migraine aggravated
Urticaria
Dyspnoea
Fatigue
Tachycardia
Vagal reaction
Dizziness
Tinnitus
Sources:
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
Disc. AE: Nausea, Lightheadedness...
AEs leading to
discontinuation/dose reduction:
Nausea (2.4%)
Lightheadedness (2.4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Angina Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Blood pressure decreased Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Cyanosis peripheral Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Dizziness Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Nausea Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Paresthesia Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Peripheral vasoconstriction Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Vomiting severe
Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, 21
Health Status: healthy
Age Group: 21
Sex: F
Sources:
Arrhythmia Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Blurred vision Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Depression Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Dizziness Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Dyspnoea Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Fatigue Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Hypersensitivity Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Migraine aggravated Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Tachycardia Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Tinnitus Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Urticaria Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Vagal reaction Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Vertigo Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy, 40+/-10
Health Status: unhealthy
Age Group: 40+/-10
Sex: M+F
Sources:
Lightheadedness 2.4%
Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
Nausea 2.4%
Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 13 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities
PubMed

PubMed

TitleDatePubMed
[Severe generalized arteriospasm after a minimal therapeutic dose of ergotamine].
1972 Dec 14
[Chronic ergotamine poisoning after migraine treatment].
1974
[Ergotamine as a cause of arterial insufficiency].
1974 Oct 10
Ergot-induced vasospasm of the lower extremities treated with epidural anaesthesia.
1975
[A case of hyposphygmia caused by ergotamine in migraine].
1975 Feb 21
[Letter: Coronary spasm following ergotamine medication].
1975 Sep 5
Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.
1980 Dec 13
[A case report of acute myocardial infarction induced by ergotamine tartrate (author's transl)].
1981 Mar
Myocardial infarction following administration of sublingual ergotamine.
1982 Sep
[Ergotism causing peripheral arterial occlusion in the hand].
1983 Mar
Screening for new compounds with antiherpes activity.
1984 Oct
[Ergotism with cerebral complications. Case report and review of the literature].
1986 Apr 5
Amelioration of ergotamine withdrawal symptoms with naproxen.
1987 Mar
Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature.
1990 Jan
[Migraine caused by ergotamine tartrate dependence].
1992 Jul
Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.
1992 Jun 15
[Daily chronic headache in patients with migraine induced by abuse of ergotamine-analgesics: response due to a protocol of outpatient treatment].
1993 Aug-Sep
Ergotamine-induced fetal stress: review of side effects of ergot alkaloids during pregnancy.
1993 Sep
[Ergotamine-induced rectal lesions in asymptomatic patients].
1994
Variant angina complicating ergot therapy of migraine.
1994 Apr
Ergot induced peripheral vascular insufficiency, non-interventional treatment.
1994 Mar
Ergotamine-induced headache can be sustained by sumatriptan daily intake.
1994 Oct
Transcranial Doppler ultrasonographic features during drug withdrawal from drug-induced headache. A transcranial Doppler follow-up study.
1998 Oct
Ergotamine-induced intermittent claudication.
1999 May
Ventricular fibrillation secondary to ergotamine in a healthy young woman.
1999 Oct
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
2000 Dec 5
Acute tubulo-interstitial nephritis and renal infarction secondary to ergotamine therapy.
2000 Nov
Ergotamine, dihydroergotamine: current uses and problems.
2001
Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution.
2001 Apr 27
Ergotamine-induced acute vascular insufficiency of the lower limb--a case report.
2001 Mar
Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature.
2002 Apr
Fibrotic valvular heart disease subsequent to bromocriptine treatment.
2002 Nov-Dec
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
2004 Aug
[Transient global amnesia following the use of ergots in the treatment of migraine].
2004 Nov 16-30
Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers.
2005 Oct
Drug-induced fibrotic valvular heart disease.
2009 Aug 15
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
Patents

Patents

Sample Use Guides

MIGERGOT - ergotamine tartrate and caffeine rectal suppository. One suppository at start of attack; second suppository after 1 hour, if needed for full relief. Two suppositories is the maximum dose for an individual attack. Cafergot (Ergotamine tartrate 1 mg and Caffeine 100 mg Tablets) First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. ERGOMAR SUBLINGUAL- ergotamine tartrate tablet For best results, dosage should start at the first sign of an attack. Early Administration Gives Maximum Effectiveness. At the first sign of an attack or to relieve symptoms after onset of an attack, one 2 mg tablet is placed under the tongue. Another tablet should be taken at half-hour intervals thereafter, if necessary, but dosage must not exceed three tablets in any 24hour period. Total weekly dosage should not exceed five tablets (10 mg) in any one week. Ergomar® Sublingual Tablets should not be used for chronic daily administration.
Route of Administration: Other
In Vitro Use Guide
The bovine anterior pituitary cells were implanted on culture tubes using D-valine minimal essential medium with serum to suppress the overgrowth of fibroblasts and then maintained in L-valine Dulbecco's modified Eagle medium. (3H)-Uridine uptake by these cells was suppressed by ergotamine at a concentration varing from 1-10 uM
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:10 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:10 GMT 2025
Record UNII
PR834Q503T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERGOTAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NSC-95090
Preferred Name English
ERGOTAMINE [HSDB]
Common Name English
Ergotamine [WHO-DD]
Common Name English
ERGOTAMINE [VANDF]
Common Name English
ERGOTAMINE [MI]
Common Name English
ergotamine [INN]
Common Name English
5??-benzyl-12?-hydroxy-2?-methyl-3?,6?,18-trioxoergotaman
Systematic Name English
ERGOTAMAN-3',6',18-TRIONE, 12'-HYDROXY-2'-METHYL-5'-(PHENYLMETHYL)-, (5'.ALPHA.)-
Common Name English
CODERGOCRINE MESILATE IMPURITY C [EP IMPURITY]
Common Name English
Classification Tree Code System Code
DEA NO. 8676
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
NDF-RT N0000007621
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
NCI_THESAURUS C47794
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
NDF-RT N0000007621
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
WHO-ATC N02CA72
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
WHO-VATC QN02CA52
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
WHO-ATC N02CA02
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
LIVERTOX 363
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
NDF-RT N0000175766
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
WHO-ATC N02CA52
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
WHO-VATC QN02CA02
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
WHO-VATC QN02CA72
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
Code System Code Type Description
DRUG CENTRAL
1043
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
INN
391
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
CAS
113-15-5
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
NCI_THESAURUS
C61751
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
EVMPD
SUB06598MIG
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
IUPHAR
149
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
CHEBI
64318
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
DRUG BANK
DB00696
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
MESH
D004878
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
EPA CompTox
DTXSID9043774
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
FDA UNII
PR834Q503T
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
LACTMED
Ergotamine
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
NSC
95090
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
DAILYMED
PR834Q503T
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
RXCUI
4025
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY RxNorm
SMS_ID
100000084579
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
MERCK INDEX
m4988
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY Merck Index
PUBCHEM
8223
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
HSDB
4076
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
WIKIPEDIA
ERGOTAMINE
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-023-9
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
ChEMBL
CHEMBL442
Created by admin on Mon Mar 31 17:34:10 GMT 2025 , Edited by admin on Mon Mar 31 17:34:10 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY